ES2929579T3 - Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes - Google Patents

Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes Download PDF

Info

Publication number
ES2929579T3
ES2929579T3 ES15799765T ES15799765T ES2929579T3 ES 2929579 T3 ES2929579 T3 ES 2929579T3 ES 15799765 T ES15799765 T ES 15799765T ES 15799765 T ES15799765 T ES 15799765T ES 2929579 T3 ES2929579 T3 ES 2929579T3
Authority
ES
Spain
Prior art keywords
seq
skin
composition
filaggrin
cell culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15799765T
Other languages
English (en)
Spanish (es)
Inventor
Azim Munivar
Travis Whitfill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azitra Inc
Original Assignee
Azitra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azitra Inc filed Critical Azitra Inc
Application granted granted Critical
Publication of ES2929579T3 publication Critical patent/ES2929579T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
ES15799765T 2014-05-30 2015-05-28 Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes Active ES2929579T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462005652P 2014-05-30 2014-05-30
US201462005558P 2014-05-30 2014-05-30
PCT/US2015/032972 WO2015184134A1 (en) 2014-05-30 2015-05-28 Therapeutic tratment of skin disease with recombinant commensal skin microorganisms

Publications (1)

Publication Number Publication Date
ES2929579T3 true ES2929579T3 (es) 2022-11-30

Family

ID=54699800

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15799765T Active ES2929579T3 (es) 2014-05-30 2015-05-28 Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes

Country Status (6)

Country Link
US (3) US10702558B2 (2)
EP (2) EP4144756A1 (2)
JP (2) JP6810028B2 (2)
ES (1) ES2929579T3 (2)
MA (1) MA40057A (2)
WO (1) WO2015184134A1 (2)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4144756A1 (en) 2014-05-30 2023-03-08 Azitra, Inc. Therapeutic treatment of skin disease with recombinant commensal skin microorganisms
US9889165B2 (en) 2016-04-21 2018-02-13 Naked Biome, Inc. Compositions and methods for treatment of skin disorders
WO2018232300A1 (en) * 2017-06-16 2018-12-20 Azitra Inc Compositions and methods for treatment of netherton syndrome with lekti expressing recombinant microbes
MX2020002013A (es) * 2017-08-31 2020-07-13 Univ California Bacterioterapia molecular para control de la actividad enzimatica de la piel.
KR102834865B1 (ko) * 2017-09-05 2025-07-17 아지트라 인코포레이티드 재조합 미생물을 사용하여 염증성 피부 질환을 치료하기 위한 방법 및 조성물
AU2018379996A1 (en) 2017-12-05 2020-06-25 BioPlx, Inc. Methods and compositions to prevent microbial infection
JP7121969B2 (ja) * 2018-02-23 2022-08-19 株式会社北里コーポレーション 培養液保護用液状物
CN112236153B (zh) * 2018-04-05 2025-04-29 阿兹特拉公司 用重组微生物治疗皮肤疾病的方法和组合物
AU2019203692B2 (en) * 2018-08-30 2024-12-12 Kenvue Brands Llc Topical composition containing glycerin and yeast extract
CA3266235A1 (en) * 2018-09-26 2025-11-29 Krystal Biotech, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES
US20210355192A1 (en) * 2018-10-08 2021-11-18 Yale University Selective Binding and Aggregation of Human Keratin in the Skin Barrier Using Human Filaggrin Subdomains SD67 and SD150
AU2019378003A1 (en) * 2018-11-16 2021-05-20 Azitra Inc Auxotrophic strains of Staphylococcus bacterium
CZ308231B6 (cs) * 2019-02-11 2020-03-11 BiomCare s.r.o. Kombinované několikastupňové mikrobiální přípravky a způsob jejich aplikace
EP3946412A4 (en) * 2019-04-05 2023-01-04 Azitra, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF ATOPIC DERMATITIS WITH RECOMBINANT MICROORGANISMS
CA3143498A1 (en) * 2019-06-19 2020-12-24 Chan Zuckerberg Biohub, Inc. Bacteria-engineered to elicit antigen-specific t-cells
KR20220133262A (ko) * 2020-01-29 2022-10-04 더 잭슨 래보라토리 박테리아 혼합물
WO2022087065A1 (en) * 2020-10-21 2022-04-28 The Jackson Laboratory Antimicrobial biosensors
JP2024506463A (ja) * 2021-01-05 2024-02-14 ラクトバイオ アー／エス 菌株、組成物および使用方法
CA3228922A1 (en) * 2021-10-11 2023-04-20 Ajinomoto Co., Inc. Bacterium modified to express heterologous tat protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0637384B2 (ja) * 1985-09-21 1994-05-18 株式会社資生堂 皮膚化粧料
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
DE4221268C2 (de) 1992-06-26 1997-06-12 Lancaster Group Ag Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut
DE4221255C2 (de) 1992-06-26 1994-09-15 Lancaster Group Ag Phospholipide enthaltendes Kosmetikum
US20120295952A1 (en) * 2009-09-25 2012-11-22 Curna, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
ES2645416T3 (es) 2009-11-23 2017-12-05 Research Development Foundation Polipéptidos de filagrina recombinantes para la importación a células
WO2011150127A2 (en) 2010-05-25 2011-12-01 The Board Of Trustees Of The University Of Illinois Novel systems, vectors, and methods for delivery of biomolecules to eukaryotic cells
MX2015001751A (es) * 2012-08-07 2015-11-13 Topgenix Inc Composicion topica comprendiendo bacterias transformadas que expresan un compuesto de interes.
KR101491240B1 (ko) 2013-03-15 2015-02-11 현대자동차주식회사 인비저블 슬라이딩 도어 링크 구조
EP4144756A1 (en) 2014-05-30 2023-03-08 Azitra, Inc. Therapeutic treatment of skin disease with recombinant commensal skin microorganisms

Also Published As

Publication number Publication date
WO2015184134A1 (en) 2015-12-03
JP6810028B2 (ja) 2021-01-06
EP3148569A1 (en) 2017-04-05
US20180161380A1 (en) 2018-06-14
US10702558B2 (en) 2020-07-07
EP3148569A4 (en) 2017-11-22
CA2979079A1 (en) 2015-12-03
JP2017518370A (ja) 2017-07-06
US12036248B2 (en) 2024-07-16
EP3148569B1 (en) 2022-07-06
US20250009810A1 (en) 2025-01-09
US20210379120A1 (en) 2021-12-09
MA40057A (fr) 2015-12-03
JP2021038271A (ja) 2021-03-11
EP4144756A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
ES2929579T3 (es) Tratamiento terapéutico de enfermedades cutáneas con microorganismos cutáneos comensales recombinantes
ES2702490T3 (es) Bacterias probióticas para el tratamiento tópico de trastornos de la piel
KR102834865B1 (ko) 재조합 미생물을 사용하여 염증성 피부 질환을 치료하기 위한 방법 및 조성물
JP2023138994A (ja) Ｌｅｋｔｉ発現組換え微生物を用いたネザートン症候群の処置のための組成物および方法
WO2004052308A2 (en) Topical anti-infective formulations
US20210070823A1 (en) Methods and compositions for treating atopic dermatitis with recombinant microorganisms
CN115317393A (zh) 用于改善哺乳动物毛囊、头皮或毛发健康的方法和组合物
US20240010970A1 (en) Antimicrobial biosensors
CN116350529A (zh) 用于改善或维持哺乳动物皮肤健康的方法和组合物
HK1236133B (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
HK1236133A1 (en) Therapeutic tratment of skin disease with recombinant commensal skin microorganisms
KR20230143154A (ko) 유전자 조작된 박테리아에서 단백질 발현을 증가시키기 위한 방법 및 조성물
Katole et al. DEVELOPMENT AND OPTIMIZATION OF SILVER NITRATE AND MAFENIDE ACETATE-LOADED ETHOSOMES FOR ENHANCED BURN WOUND HEALING.
WO2024118471A1 (en) Antimicrobial biosensors
WO2019079150A1 (en) COMPOSITIONS AND METHODS FOR TREATING ATOPIC DERMATITIS
JP2025504990A (ja) Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｅｐｉｄｅｒｍｉｄｉｓの染色体からのヒトｌｅｋｔｉ遺伝子の発現
EP3630081A1 (en) Xibornol for use in the treatment of acne vulgaris
ES2387425A1 (es) Composición para el tratamiento de infecciones bacterianas de la piel y mucosas